Long-term effect of metformin on metabolic parameters in the polycystic ovary syndrome

Diabetes and Vascular Disease Research

Volumn 6, Issue 2, 2009, Pages 110-119

  Cheang, Kai I ^a   Huszar, Jessica M ^a   Best, Al M ^a   Sharma, Susmeeta ^a   Essah, Paulina A ^a   Nestler, John E ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Cardiovascular risk factors; Metabolic syndrome; Metformin; Polycystic ovary syndrome

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; METFORMIN;

ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG DOSE TITRATION; FEMALE; FOLLOW UP; HUMAN; INSULIN RESISTANCE; LONG TERM CARE; MAJOR CLINICAL STUDY; MAXIMUM TOLERATED DOSE; METABOLIC DISORDER; METABOLIC REGULATION; METABOLIC SYNDROME X; OVARY POLYCYSTIC DISEASE; RISK FACTOR; TREATMENT OUTCOME;

ADULT; BLOOD PRESSURE; BODY MASS INDEX; CHOLESTEROL, HDL; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; METABOLIC SYNDROME X; METFORMIN; POLYCYSTIC OVARY SYNDROME; PREVALENCE; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 68349099934     PISSN: 14791641     EISSN: None     Source Type: Journal    
DOI: 10.1177/1479164109336050     Document Type: Article

References (47)

1. Asuncion, M, Calvo, RM, San Millan, JL, Sancho, J, Avila, S, Escobar-Morreale, HF (2000) A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 85: 2434-2438 (Pubitemid 32269197)
2. Knochenhauer, ES, Key, TJ, Kahsar-Miller, M, Waggoner, W, Boots, LR, Azziz, R (1998) Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 83: 3078-3082 (Pubitemid 28500937)
3. Legro, RS, Kunselman, AR, Dodson, WC, Dunaif, A (1999) Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 84: 165-169 (Pubitemid 29036695)
4. Nestler, JE (1997) Role of hyperinsulinemia in the pathogenesis of the polycystic ovary syndrome, and its clinical implications. Semin Reprod Endocrinol 15: 111-122
5. Nestler, JE, Jakubowicz, DJ (1997) Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17 alpha activity and serum androgens. J Clin Endocrinol Metab 82: 4075-4079
6. Nestler, JE, Jakubowicz, DJ (1996)Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med 335: 617-623
7. Lo, JC, Feigenbaum, SL, Yang, J, Pressman, AR, Selby, JV, Go, AS (2006) Epidemiology and adverse cardiovascular risk profile of diagnosed polycystic ovary syndrome. J Clin Endocrinol Metab 91: 1357-1363
8. Dunaif, A (1995) Hyperandrogenic anovulation (PCOS): a unique disorder of insulin action associated with an increased risk of non-insulin-dependent diabetes mellitus. Am J Med 98: 33S-9S.
9. Ehrmann, DA, Barnes, RB, Rosenfield, RL, Cavaghan, MK, Imperial, J (1999) Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 22: 141-146 (Pubitemid 29028311)
10. Haffner, SM, D'Agostino, R, Jr, Festa, A, et al. (2003) Low insulin sensitivity (S(i) = 0) in diabetic and nondiabetic subjects in the insulin resistance atherosclerosis study: is it associated with components of the metabolic syndrome and nontraditional risk factors? Diabetes Care 26: 2796-2803
11. Hanley, AJ, D'Agostino, R, Jr, Wagenknecht, LE, et al. (2002) Increased proinsulin levels and decreased acute insulin response independently predict the incidence of type 2 diabetes in the insulin resistance atherosclerosis study. Diabetes 51: 1263-1270
12. Grundy, SM, Cleeman, JI, Daniels, SR, et al. (2005) Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112: 2735-2752
13. Haffner, SM, Valdez, RA, Hazuda, HP, Mitchell, BD, Morales, PA, Stern, MP (1992) Prospective analysis of the insulin-resistance syndrome (syndrome X). Diabetes 41: 715-722
14. Isomaa, B, Almgren, P, Tuomi, T, et al. (2001) Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24: 683-689 (Pubitemid 32893993)
15. Trevisan, M, Liu, J, Bahsas, FB, Menotti, A Risk Factor and Life Expectancy Research Group. (1998) Syndrome X and mortality: a population-based study. Am J Epidemiol 148: 958-966
16. Glueck, CJ, Papanna, R, Wang, P, Goldenberg, N, Sieve-Smith, L (2003) Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. Metabolism 52: 908-915 (Pubitemid 36957780)
17. Apridonidze, T, Essah, PA, Iuorno, MJ, Nestler, JE (2005) Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 90: 1929-1935 (Pubitemid 40586223)
18. Ehrmann, DA, Liljenquist, DR, Kasza, K, Azziz, R, Legro, RS, Ghazzi, MN (2006) Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 91: 48-53. (Pubitemid 43069116)
19. Ford, ES, Giles, WH, Dietz, WH (2002) Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 287: 356-359 (Pubitemid 34251969)
20. Lord, JM, Flight, IH, Norman, RJ (2003) Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ 327: 951-953
21. Diabetes Prevention Program Research Group. (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346: 393-403.
22. Orchard, TJ, Temprosa, M, Goldberg, R, et al. (2005) The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med 142: 611-619 (Pubitemid 40529957)
23. de Aguiar, LG, Bahia, LR, Villela, N, et al. (2006) Metformin improves endothelial vascular reactivity in first-degree relatives of type 2 diabetic patients with metabolic syndrome and normal glucose tolerance. Diabetes Care 29: 1083-1089 (Pubitemid 44115248)
24. Vitale, C, Mercuro, G, Cornoldi, A, Fini, M, Volterrani, M, Rosano, GM (2005) Metformin improves endothelial function in patients with metabolic syndrome. J Intern Med 258: 250-256 (Pubitemid 41243057)
25. Goldenberg, N, Glueck, CJ, Loftspring, M, Sherman, A, Wang, P (2005) Metformin-diet benefits in women with polycystic ovary syndrome in the bottom and top quintiles for insulin resistance. Metabolism 54: 113-121 (Pubitemid 39572466)
26. Lord, J, Thomas, R, Fox, B, Acharya, U, Wilkin, T (2006) The effect of metformin on fat distribution and the metabolic syndrome in women with polycystic ovary syndrome - a randomised, double-blind, placebo-controlled trial. BJOG 113: 817-824 (Pubitemid 43961744)
27. Meyer, C, McGrath, BP, Teede, HJ (2007) Effects of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome. Diabetes Care 30: 471-478 (Pubitemid 46354320)
28. Morin-Papunen, L, Rautio, K, Ruokonen, A, Hedberg, P, Puukka, M, Tapanainen, JS (2003) Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab 88: 4649-4654 (Pubitemid 37357506)
29. Orio, F, Manguso, F, Di Biase, S, et al. (2007) Metformin administration improves leukocyte count in women with polycystic ovary syndrome: a 6-month prospective study. Eur J Endocrinol 157: 69-73. (Pubitemid 47162568)
30. Tang, T, Glanville, J, Hayden, CJ, White, D, Barth, JH, Baien, AH (2006) Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study. Hum Reprod 21: 80-89.
31. Glueck, CJ, Aregawi, D, Agloria, M, Winiarska, M, Sieve, L, Wang, P (2006) Sustainability of 8% weight loss, reduction of insulin resistance, and amelioration of atherogenic-metabolic risk factors over 4 years by metformin-diet in women with polycystic ovary syndrome. Metabolism 55: 1582-1589 (Pubitemid 44827123)
32. Zawadzki, JK, Dunaif, A Diagnostic Criteria for Polycystic Ovary Syndrome: Towards a Rational Approach (pp 377-84). Boston, MA: Blackwell Scientific, 1992.
33. Genuth, S, Alberti, KG, Bennett, P, et al. (2003) Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 26: 3160-3167 (Pubitemid 37339514)
34. Ridker, PM, Buring, JE, Cook, NR, Rifai, N (2003) C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 107: 391-397
35. Ninomiya, JK, L'Italien, G, Criqui, MH, Whyte, JL, Gamst, A, Chen, RS (2004) Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey. Circulation 109: 42-46. (Pubitemid 38056019)
36. Cobin, RH, Futterweit, W, Nestler, JE, et al. (2005) American Association of Clinical Endocrinologists Position Statement on Metabolic and Cardiovascular Consequences of Polycystic Ovary Syndrome. Endocr Pract 11: 125-134
37. Krstevska, B, Dimitrovski, C, Pemovska, G, et al. (2006) Metformin improves menstrual patterns, endocrine and metabolic profile in obese hyperinsulinemic women with a polycystic ovary syndrome. Prilozi 27: 57-66.
38. Moghetti, P, Castello, R, Negri, C, et al. (2000) Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab 85: 139-146 (Pubitemid 32268804)
39. Norman, RJ, Davies, MJ, Lord, J, Moran, LJ (2002) The role of lifestyle modification in polycystic ovary syndrome. Trends Endocrinol Metab 13: 251-257 (Pubitemid 36733970)
40. Ehrmann, DA, Cavaghan, MK, Imperial, J, Sturis, J, Rosenfield, RL, Polonsky, KS (1997) Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 82: 524-530
41. Sahin, Y, Unluhizarci, K, Yilmazsoy, A, Yikilmaz, A, Aygen, E, Kelestimur, F (2007) The effects of metformin on metabolic and cardiovascular risk factors in non-obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 67: 904-908 (Pubitemid 350135135)
42. Trolle, B, Flyvbjerg, A, Kesmodel, U, Lauszus, FF (2007) Efficacy of metformin in obese and non-obese women with polycystic ovary syndrome: a randomized, double-blinded, placebo-controlled cross-over trial. Hum Reprod 22: 2967-2973 (Pubitemid 351696807)
43. Tan, S, Hahn, S, Benson, S, et al. (2007) Metformin improves polycystic ovary syndrome symptoms irrespective of pre-treatment insulin resistance. Eur J Endocrinol 157: 669-676 (Pubitemid 350187385)
44. Legro RS, Gnatuk CL, Kunselman AR, Dunaif A. Changes in glucose tolerance over time in women with polycystic ovary syndrome: a controlled study. J Clin Endocrinol Metab 2005; 90: 3236-3242 (Pubitemid 41014281)
45. Norman, RJ, Masters, L, Milner, CR, Wang, JX, Davies, MJ (2001) Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome. Hum Reprod 16: 1995-1998 (Pubitemid 32916235)
46. Diabetes Prevention Program Research Group. (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346: 393-403.
47. Meigs, JB, Wilson, PW, Nathan, DM, D'Agostino, RB, Sr., Williams, K, Haffner, SM (2003) Prevalence and characteristics of the metabolic syndrome in the San Antonio Heart and Framingham Offspring Studies. Diabetes 52: 2160-2167 (Pubitemid 36919812)